Literature DB >> 6690053

Prognostic significance of nuclear DNA content in mammary adenocarcinomas in humans.

G Auer, E Eriksson, E Azavedo, T Caspersson, A Wallgren.   

Abstract

The value of the determination of the DNA content of tumor cells for the assessment of the prognosis of mammary adenocarcinoma was studied in 36 patients, who survived for at least 15 years after the cancer had been found and in another 42 patients who died within a 2-year period of diagnosis. The results show a distinct correlation between the type of the DNA histograms of the carcinoma and the grade of cancer. This correlation was particularly apparent among patients surviving for at least 15 years despite the occurrence of metastases or relapses after primary treatment, i.e., in patients not cured by their first treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6690053

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

Review 1.  Aneuploidy as a prognostic factor in breast cancer.

Authors:  A von Rosen
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Genome Instability Profiles Predict Disease Outcome in a Cohort of 4,003 Patients with Breast Cancer.

Authors:  Annette Lischka; Natalie Doberstein; Sandra Freitag-Wolf; Ayla Koçak; Timo Gemoll; Kerstin Heselmeyer-Haddad; Thomas Ried; Gert Auer; Jens K Habermann
Journal:  Clin Cancer Res       Date:  2020-06-10       Impact factor: 12.531

3.  Biological grading of breast cancer using antibodies to proliferating cells and other markers.

Authors:  S S Bacus; R Goldschmidt; D Chin; G Moran; D Weinberg; J W Bacus
Journal:  Am J Pathol       Date:  1989-11       Impact factor: 4.307

4.  Nuclear DNA content of borderline tumors of the ovary: correlation with histology and significance for prognosis.

Authors:  M Dietel; H Arps; A Rohlff; R Bodecker; A Niendorf
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1986

5.  Aneuploidy, TP53 mutation, and amplification of MYC correlate with increased intratumor heterogeneity and poor prognosis of breast cancer patients.

Authors:  Johanna Oltmann; Kerstin Heselmeyer-Haddad; Leanora S Hernandez; Rüdiger Meyer; Irianna Torres; Yue Hu; Natalie Doberstein; J Keith Killian; David Petersen; Yuelin Jack Zhu; Daniel C Edelman; Paul S Meltzer; Russell Schwartz; E Michael Gertz; Alejandro A Schäffer; Gert Auer; Jens K Habermann; Thomas Ried
Journal:  Genes Chromosomes Cancer       Date:  2018-01-09       Impact factor: 5.006

Review 6.  The consequences of chromosomal aneuploidy on the transcriptome of cancer cells.

Authors:  Thomas Ried; Yue Hu; Michael J Difilippantonio; B Michael Ghadimi; Marian Grade; Jordi Camps
Journal:  Biochim Biophys Acta       Date:  2012-03-06

7.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

8.  Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.

Authors:  Kerstin Heselmeyer-Haddad; Lissa Y Berroa Garcia; Amanda Bradley; Clarymar Ortiz-Melendez; Woei-Jyh Lee; Rebecca Christensen; Sheila A Prindiville; Kathleen A Calzone; Peter W Soballe; Yue Hu; Salim A Chowdhury; Russell Schwartz; Alejandro A Schäffer; Thomas Ried
Journal:  Am J Pathol       Date:  2012-10-08       Impact factor: 4.307

9.  Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.

Authors:  H Schimmelpenning; E T Eriksson; U G Falkmer; E Azavedo; G Svane; G U Auer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

10.  Markers of prognosis in breast cancer--the relationship between binding of the lectin HPA and histological grade, SPF, and ploidy.

Authors:  S A Brooks; A J Leathem; R S Camplejohn; W Gregory
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.